Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Unlike CJC-1295, it lacks the modifications that provide DPP-IV resistance
The injectable obesity medications Semaglutide 2.4 mg, a selective GLP-1 receptor agonist, produces robust and durable weight loss of approximately 1516% over 68 weeks ( Tirzepatide, a dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonist, delivers even greater weight loss, exceeding 20% at the highest dose in pivotal trials ( Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, represents a further step in efficacy, with 24.2% weight loss achieved within 48 weeks in phase 2 studies ( Survodutide, an oxyntomodulin analogue, achieved clinically meaningful weight loss ( Table 2
More Mechanisms = More Potential Risks: Because Retatrutide is a triple agonist, it may come with more side effects and unknown long-term risks, including GI issues, nerve-related symptoms, and possible heart concerns
Semaglutide is used in weight loss after the 2014 clinical trial showed 50% of patients lost 15% of body weight
People with underlying health conditions, individuals on medications, or those with specific dietary needs should consult their healthcare providers before making significant changes to their diet
GLP-1 medications are contraindicated in pregnancy and should be discontinued at least two months before attempting to conceive discuss family planning with your provider before starting treatment
